levopropoxyphene

Trade name: Novrad

Small moleculeapproved

Approved

Mar 21, 1962

LEVOPROPOXYPHENE is an antitussive drug, one of enantiomer of propoxyphene. Pdropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. Pdropoxyphene is intended to treat mild pain and also has antitussive (cough suppressant) and local anaesthetic effects. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1960s

Mar 21, 1962
Eli Lilly — Earliest FDA Approval
Mar 21, 1962
Eli Lilly — NDA Organization

Indications

Approved for

Pain (approved 1962)

Mechanism of action

Cannabinoid receptor 1/Mu-type opioid receptorAGONIST
Cannabinoid receptor 1/Mu-type opioid receptor agonist
- Cannabinoid receptor 1 (CNR1) ↗
- Mu-type opioid receptor (OPRM) ↗
- Cannabinoid CB1 receptor
- Mu opioid receptor

Approval history

approvedMar 21, 1962

Chemistry & pharmacology

Loading structure…

SMILES

CCC(=O)O[C@](CC1=CC=CC=C1)([C@@H](C)CN(C)C)C2=CC=CC=C2

Mol. weight: 339.4712 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Black box warning

Sources

Also known as

levopropoxyphene
levopropoxyphene
levopropoxyphene
levopropoxyphene
levopropoxyphene
levopropoxyphene
levopropoxyphene
levopropoxyphene
levopropoxyphene napsylate
levopropoxyphene napsylate
levopropoxyphene napsylate anhydrous
levopropoxyphene napsylate anhydrous
levopropoxyphene napsylate anhydrous
levopropoxyphene napsylate, anhydrous
(l)-propoxyphene
(l)-propoxyphene
l-propoxyphene
novrad
novrad
novrad
(-)-propoxyphene
(-)-propoxyphene

Organizations

Marketing (1)

Organization	Org type	Relationship	Date
Eli Lilly	For profit	NDA	Mar 21, 1962